Market News & Trends
Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of Drug-Enhanced Cell Therapy for the Treatment of Patients With Solid Tumors
Nurix Therapeutics, Inc. recently announced the first patient has been dosed in its Phase 1 clinical trial of DeTIL-0255, a drug-enhanced tumor infiltrating lymphocyte therapy and….
Sterling Pharma Solutions Expands Capabilities & Laboratory Capacity
Sterling Pharma Solution recently announced a £1 million expansion project at its Deeside, UK site, which is the company’s dedicated bioconjugation and antibody-drug conjugates (ADCs)…
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Potential First-in-Class Oncolytic Peptide-Based Immunotherapy
Verrica Pharmaceuticals Inc. recently announced the first patient has been dosed in the company’s Phase 2 trial of LTX-315, a potential first-in-class oncolytic peptide, for the….
Processa Pharmaceuticals Announces First Patient Enrolled in Phase 2A Trial for the Treatment of Gastroparesis
Processa Pharmaceuticals, Inc. recently announced it has enrolled its first patient in the Phase 2A clinical trial of PCS12852 in patients with moderate-to-severe gastroparesis. Gastroparesis…
Agenus’ CD137 Agonist Advances in the Clinic, Triggering Milestone Payment From Gilead
Agenus Inc. recently announced receipt of a $5-million clinical milestone payment for AGEN2373 (conditionally active CD137 agonist). AGEN2373 is being evaluated in a Phase 1b…
UK Government to Support Expansion of Croda’s Lipid Systems Manufacturing Facility
Croda International Plc that uses smart science to create high performance ingredients and solutions that improve lives, recently announced that it has been awarded a £15.9 million grant by the UK Government to expand….
New BD Assay Advances Immunology Research Capabilities in the Developing Field of Multiomics
BD (Becton, Dickinson and Company) recently released the BD Rhapsody TCR/BCR Multiomic Assay, an innovative set of reagents that enables researchers to more easily and…
Proveris Expands Product Portfolio With New Kinaero Cx pMDI Collection System for Delivered Dose Uniformity & Aerodynamic Particle Size Distribution Testing
Proveris Scientific Corporation recently introduced the Kinaero Cx pMDI Collection System to automate the pMDI shaking, priming, dose sample collection, and fire-down for….
Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator
Athira Pharma, Inc. recently announced that the first subject has been dosed in a Phase 1 clinical trial investigating ATH-1020, an orally available,….
Starton Therapeutics Announces FDA Clearance of IND Application
Starton Therapeutics Inc. recently announced the US FDA has cleared an investigational new drug (IND) application for STAR-OLZ in Chemotherapy Induced Nausea and Vomiting (CINV). STAR-OLZ is a multi-day transdermal….
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial
Inozyme Pharma, Inc. recently announced positive preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three patients treated in the Phase 1 portion of its…
CymaBay Therapeutics Announces Results From 52-Week, Open-Label, Phase 2 Study
CymaBay Therapeutics, Inc. recently announced that results from the Phase 2, 52-week study of seladelpar in patients with primary biliary cholangitis (PBC) have been published…
Halberd Continues In Vitro Successes With Elimination of Protein Linked to Depression
Halberd Corporation demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro. Halberd, encouraged by…
Novel Nuclear MicroRNA is Being Developed for the Treatment of Cardiovascular Disease
A novel angiogenic microRNA drug can be a new option for the treatment of ischemic cardiovascular disease, according to a new study published in PLOS…
Ocugen Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate
Ocugen, Inc. recently announced the first patient has been dosed in the Phase 1/2 clinical trial of OCU400, a modifier gene therapy candidate for the treatment of retinitis pigmentosa….
Lonza Joins IPAC-RS, an International Consortium Advancing the Regulatory Science of Inhalation Products
Lonza recently announced its membership in the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). Through this consortium, Lonza will collaborate with other industry…
Outlook Therapeutics Submits BLA to FDA for ONS-5010 as a Treatment for Wet AMD
Outlook Therapeutics, Inc. recently announced it has submitted its Biologics License Application (BLA) to the US FDA for ONS-5010, an investigational therapy which, if approved,…
Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate
AGC Biologics recently announced a new partnership with Allergy Therapeutics, the fully integrated specialty pharmaceutical company specializing in allergy vaccines. The CDMO has manufactured Phase 1…
Cidara Therapeutics Announces Completion of Dosing the First Cohort of Healthy Volunteers in Phase 1 Trial
Cidara Therapeutics, Inc. recently announced the first cohort of healthy volunteers has been dosed in its Phase 1 trial of CD388, a highly potent long-acting…
Silo Pharma Enters Agreement With CRO for Pharmacokinetic Study
Silo Pharma, Inc. recently announced it has entered into an agreement with Frontage Laboratories, a CRO providing integrated, science-driven, product development services throughout the….
